1. Home
  2. RLMD
  3. RLMD News

Latest Relmada Therapeutics Inc. (RLMD) News on February 23, 2025

Relmada acquires Tourette’s therapy rights from Asarina
RLMD

Pharmaceutical Technology

16 days ago

Relmada acquires Tourette’s therapy rights from Asarina

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
RLMD

GlobeNewswire

17 days ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

US Penny Stocks To Watch In January 2025
RLMD

Simply Wall St.

2 months ago

US Penny Stocks To Watch In January 2025

RLMD

Argus Research

2 months ago

Daily – Vickers Top Insider Picks for 12/09/2024

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
RLMD

GlobeNewswire

2 months ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/06/2024

RLMD

MT Newswires

3 months ago

Relmada Shares Continue Downward Spiral After Downgrades

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile
RLMD

TipRanks

3 months ago

Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/05/2024

RLMD

MT Newswires

3 months ago

Sector Update: Health Care Stocks Edge Lower Late Afternoon

RLMD

MT Newswires

3 months ago

Top Midday Decliners

RLMD

MT Newswires

3 months ago

Relmada Therapeutics' Late-Stage Trial of REL-1017 Deemed 'Futile' -- Shares Decline Pre-Bell

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/04/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/03/2024

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks
RLMD

Simply Wall St.

3 months ago

US Penny Stocks Spotlight: LiveOne And 2 Other Promising Picks

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 12/02/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/29/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/27/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/26/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/25/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/22/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/21/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/20/2024

Relmada Therapeutics to Present at Jefferies London Healthcare Conference
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics to Present at Jefferies London Healthcare Conference

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/19/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/18/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/15/2024

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
RLMD

GlobeNewswire

3 months ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/14/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/13/2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/11/2024

RLMD

Market Exclusive

3 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024

RLMD

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 11/08/2024

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...
RLMD

GuruFocus.com

3 months ago

Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ...

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
RLMD

PR Newswire

4 months ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/07/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/06/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/05/2024

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
RLMD

GlobeNewswire

4 months ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/04/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 11/01/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/31/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/30/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/29/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/28/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/25/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/24/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/23/2024

3 US Penny Stocks To Monitor In October 2024
RLMD

Simply Wall St.

4 months ago

3 US Penny Stocks To Monitor In October 2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/22/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/21/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/18/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/17/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/16/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/15/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/14/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/11/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/10/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/09/2024

RLMD

Argus Research

4 months ago

Daily – Vickers Top Insider Picks for 10/08/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/07/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/04/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/03/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/02/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 10/01/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/30/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/27/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/26/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/25/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/24/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/23/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/20/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/19/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/18/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/17/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/16/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/13/2024

Insider Spends US$395k Buying More Shares In Relmada Therapeutics
RLMD

Simply Wall St.

5 months ago

Insider Spends US$395k Buying More Shares In Relmada Therapeutics

RLMD

Argus Research

5 months ago

Daily – Vickers Top Insider Picks for 09/12/2024

RLMD

Argus Research

5 months ago

Daily – Vickers Top Buyers & Sellers for 09/12/2024

Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)
RLMD

GuruFocus.com

5 months ago

Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)

Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares
RLMD

GuruFocus.com

5 months ago

Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares

RLMD

MT Newswires

5 months ago

Relmada Therapeutics Insider Bought Shares Worth $395,115, According to a Recent SEC Filing

Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?
RLMD

Simply Wall St.

6 months ago

Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely?

Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
RLMD

Zacks

6 months ago

Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

RLMD

Thomson Reuters StreetEvents

6 months ago

Q2 2024 Relmada Therapeutics Inc Earnings Call

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
RLMD

PR Newswire

7 months ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership
RLMD

Simply Wall St.

7 months ago

Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
RLMD

PR Newswire

8 months ago

Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
RLMD

PR Newswire

8 months ago

Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
RLMD

PR Newswire

9 months ago

Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript
RLMD

Insider Monkey

9 months ago

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript

RLMD

Thomson Reuters StreetEvents

9 months ago

Q1 2024 Relmada Therapeutics Inc Earnings Call

RLMD

GuruFocus.com

9 months ago

Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
RLMD

PR Newswire

9 months ago

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
RLMD

PR Newswire

10 months ago

Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

RLMD

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 04/29/2024

RLMD

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 04/26/2024

RLMD

Argus Research

10 months ago

Daily – Vickers Top Insider Picks for 04/25/2024

Share on Social Networks: